NATCO Pharma Dirección

Dirección controles de criterios 4/4

El CEO de NATCO Pharma's es Rajeev Nannapaneni, nombrado en Jun 2012, tiene una permanencia de 11.83 años. posee directamente un 0.63% de las acciones de la empresa, con un valor de ₹1.15B. La antigüedad media del equipo directivo y de la junta directiva es de 7.2 años y 9.3 años, respectivamente.

Información clave

Rajeev Nannapaneni

Chief Executive Officer (CEO)

₹20.9m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	11.9yrs
Participación del CEO	0.6%
Permanencia media de la dirección	7.3yrs
Promedio de permanencia en la Junta Directiva	9.4yrs

Actualizaciones recientes de la dirección

Recent updates

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Apr 03

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02

NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 22

These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well

Mar 22

Should NATCO Pharma Limited (NSE:NATCOPHARM) Be Part Of Your Dividend Portfolio?

Mar 04

CEO

Rajeev Nannapaneni (46 yo)

11.9yrs

Permanencia

₹20,920,000

Compensación

Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Venkaiah Nannapaneni	MD & Chairman	42.7yrs	₹22.68m	25.1% ₹ 46.5b
Rajeev Nannapaneni	CEO & Vice Chairman	11.9yrs	₹20.92m	0.63% ₹ 1.2b
S. V. V. Appa Rao	Chief Financial Officer	8.3yrs	₹13.00m	sin datos
Donthineni Rao	President of Technical Affairs & Whole Time Director	no data	₹32.30m	0.030% ₹ 56.0m
Chekuri Ramesh	Company Secretary & Compliance Officer	2.1yrs	₹3.00m	sin datos
Potluri Prasad	Executive VP of Corporate Engineering Services & Whole Time Director	no data	₹19.20m	0.026% ₹ 47.7m
Pavan Bhat	Executive VP of Technical Operations & Director	7.3yrs	₹54.50m	sin datos
Sanivarapu Reddy	Senior Vice President of Operations	no data	sin datos	sin datos
N. Rao	Executive Vice President of Corporate Affairs	no data	sin datos	sin datos
James Rajakumar	Vice President of Marketing & Sales - Domestic	less than a year	sin datos	sin datos
A. Lakshminarayana	Senior Vice President of HR & Organisational Development	no data	sin datos	0.0062% ₹ 11.5m
M. Reddy	Executive Vice President of R&D	30.1yrs	sin datos	sin datos

7.3yrs

Permanencia media

64yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NATCOPHARM es experimentado (7.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Venkaiah Nannapaneni	MD & Chairman	42.7yrs	₹22.68m	25.1% ₹ 46.5b
Rajeev Nannapaneni	CEO & Vice Chairman	18.5yrs	₹20.92m	0.63% ₹ 1.2b
Donthineni Rao	President of Technical Affairs & Whole Time Director	9.3yrs	₹32.30m	0.030% ₹ 56.0m
Potluri Prasad	Executive VP of Corporate Engineering Services & Whole Time Director	9.5yrs	₹19.20m	0.026% ₹ 47.7m
Pavan Bhat	Executive VP of Technical Operations & Director	1.8yrs	₹54.50m	sin datos
Thallapaka Rao	Independent Director	10.1yrs	₹620.00k	sin datos
Leela Digumarti	Independent Director	9.7yrs	₹350.00k	sin datos
Madireddi Naidu	Independent Director	9.3yrs	₹600.00k	sin datos
Agnihotra Dakshina Chavali	Independent Director	less than a year	sin datos	sin datos
Dronadula Bhaskar	Independent Director	less than a year	sin datos	sin datos

9.4yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de NATCOPHARM se considera experimentada (9.3 años de antigüedad promedio).

NATCO Pharma Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Insider recently bought ₹161k worth of stock

Recent updates

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Now 22% undervalued

Now 20% undervalued

Consensus EPS estimates increase by 17%

Investor sentiment improves as stock rises 16%

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Upcoming dividend of ₹1.25 per share

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024

NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Upcoming dividend of ₹7.00 per share at 0.7% yield

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Price target increased by 9.6% to ₹734

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings: EPS exceeds analyst expectations

NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Insider recently bought ₹161k worth of stock

NATCO Pharma Limited Files Generic Olaparib Tablets in USA

Upcoming dividend of ₹1.25 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Approves Third Interim Dividend for the Financial Year 2022-23, Payable on March 1, 2023

NATCO Pharma Limited to Report Q3, 2023 Results on Feb 09, 2023

MD & Director recently bought ₹5.0m worth of stock

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Natco Pharma Limited Announces Double Bench of the High Court of Delhi Dismiss an Appeal Filed by FMC Corporation, FMC Singapore and FMC India

Price target decreased to ₹709

Consensus EPS estimates fall by 10%

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2022-23, Payable from 30 November 2022

NATCO Pharma Limited to Report Q2, 2023 Results on Nov 10, 2022

Natco Pharma Limited Announces FMC Corporation and FMC Singapore Serve A Copy of Appeal on Natco

Natco Pharma Limited Launches Chlorantraniliprole

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2022

NATCO Announces Tentative Approval to Its ANDA for Trabectedin (Generic for Yondelis®)

Upcoming dividend of ₹3.50 per share

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on August 30, 2022

NATCO Pharma Limited to Report Q1, 2023 Results on Aug 09, 2022

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Consensus revenue estimates increase by 12%

NATCO Pharma Limited Announces the Launch of the First Generic Version of Nexavar® (Sorafenib) Tablets in 200 Mg Strength in the U.S. Market

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Price target decreased to ₹894

Full year 2022 earnings: EPS and revenues miss analyst expectations

FMC Corporation Files a Suit against NATCO Pharma Limited

NATCO Pharma Limited to Report Q4, 2022 Results on May 30, 2022

Insufficient new directors